Priyanka Ghosh
Priyanka Ghosh has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Amitabh Gulati
Memorial Sloan Kettering Cancer Center, New York, NY, USA
1 shared publication - Brandon Gish
Department of Interventional Pain, Lexington Clinic, Lexington, KY, USA
1 shared publication Brendan Langford
Division of Pain Medicine, Department of Anesthesiology Vanderbilt University Medical Center Nashville Tennessee USA
1 shared publicationChahait Singh
Empire Minimally Invasive Spine and Pain New York New York USA
1 shared publicationChristopher Sobey
Division of Pain Medicine, Department of Anesthesiology Vanderbilt University Medical Center Nashville Tennessee USA
1 shared publication- Daniel Chun‐Suk Oh
Department of Rehabilitation and Regenerative Medicine, NewYork-Presbyterian Hospital—University Hospital of Columbia and Cornell, New York, New York, USA
1 shared publication
Latest Publications
- 19 September 2023
- Published by Wiley in Pain Practice
- Vol. 24 (2) , 321-340
Neuromodulation for the management of chronic pelvic pain syndromes: A systematic review
Background: Chronic pelvic pain is a burdensome condition that involves multiple medical sub‐specialties and is often difficult to treat. Sacral stimulation for functional bladder disease has been well established, but little large‐scale evidence exists regarding utilization of other neuromodulation techniques to treat chronic pelvic pain. Emerging evidence does suggest that neuromodulation is a promising treatment, and we aim to characterize the use and efficacy of such techniques for treating chronic pelvic pain syndromes.Materials and Methods: A systematic review of the literature demonstrating the treatment of chronic pelvic pain syndromes with neuromodulation. Abstracts were reviewed and selected for inclusion, including case series, prospective studies, and randomized controlled trials (RCTs). Case studies and publications in abstract only were not included. The reporting for this systematic review follows Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA). The literature search was performed using MEDLINE, Embase, Cochrane Library, PubMed, CINAHL, and Scopus.Results: A total of 50 studies were included in this review, three of which were randomized controlled trials, and the remaining were prospective and retrospective case series. The range of pelvic pain conditions treated included interstitial cystitis, peripheral neuralgia, pudendal neuralgia, gastrointestinal pain, urogenital pain, sacroiliac joint pain, and visceral chronic pelvic pain. We reported on outcomes involving pain, functionality, psychosocial improvement, and medication reduction.Conclusions: Neuromodulation is a growing treatment for various chronic pain syndromes. Peripheral nerve stimulation was the least studied form of stimulation. Posterior tibial nerve stimulation appears to offer short‐term benefit, but long‐term results are challenging. Sacral nerve stimulation is established for use in functional bladder syndromes and appears to offer pain improvement in these patients as well. Dorsal root ganglion stimulation and spinal cord stimulation have been used for a variety of conditions with promising results. Further studies of homogeneous patient populations are necessary before strong recommendations can be made at this time, although pooled analysis may also be impactful.
- 19 September 2023
- Published by Wiley in Pain Practice
- Vol. 24 (2) , 321-340
Neuromodulation for the management of chronic pelvic pain syndromes: A systematic review
Background: Chronic pelvic pain is a burdensome condition that involves multiple medical sub‐specialties and is often difficult to treat. Sacral stimulation for functional bladder disease has been well established, but little large‐scale evidence exists regarding utilization of other neuromodulation techniques to treat chronic pelvic pain. Emerging evidence does suggest that neuromodulation is a promising treatment, and we aim to characterize the use and efficacy of such techniques for treating chronic pelvic pain syndromes.Materials and Methods: A systematic review of the literature demonstrating the treatment of chronic pelvic pain syndromes with neuromodulation. Abstracts were reviewed and selected for inclusion, including case series, prospective studies, and randomized controlled trials (RCTs). Case studies and publications in abstract only were not included. The reporting for this systematic review follows Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA). The literature search was performed using MEDLINE, Embase, Cochrane Library, PubMed, CINAHL, and Scopus.Results: A total of 50 studies were included in this review, three of which were randomized controlled trials, and the remaining were prospective and retrospective case series. The range of pelvic pain conditions treated included interstitial cystitis, peripheral neuralgia, pudendal neuralgia, gastrointestinal pain, urogenital pain, sacroiliac joint pain, and visceral chronic pelvic pain. We reported on outcomes involving pain, functionality, psychosocial improvement, and medication reduction.Conclusions: Neuromodulation is a growing treatment for various chronic pain syndromes. Peripheral nerve stimulation was the least studied form of stimulation. Posterior tibial nerve stimulation appears to offer short‐term benefit, but long‐term results are challenging. Sacral nerve stimulation is established for use in functional bladder syndromes and appears to offer pain improvement in these patients as well. Dorsal root ganglion stimulation and spinal cord stimulation have been used for a variety of conditions with promising results. Further studies of homogeneous patient populations are necessary before strong recommendations can be made at this time, although pooled analysis may also be impactful.
- 6 October 2020
- Published by Wiley in Pain Practice
- Vol. 21 (3) , 285-298
Epidural Steroid Injections for the Management of Spinal Malignancy‐Related Pain: A Pragmatic Review and Retrospective Study
Background: Spinal malignancy‐related pain results from tumor, fracture, instability, inflammation, and/or nerve root/spinal cord compression. Systemic corticosteroids are commonly used but have many undesirable adverse effects that impact quality of life and continuation of cancer treatments. Epidural steroid injections (ESIs) may be a viable alternative pain treatment.Objectives: This study starts with a pragmatic review on the efficacy of ESIs to treat spinal malignancy‐related pain. Given the limited evidence, we supplement the study with a single‐center, retrospective review.Methods: A pragmatic review using PRISMA guidelines was conducted in MEDLINE, EMBASE, SCOPUS, and Cochrane Review. Then, a retrospective chart review was performed.Results: A pragmatic review yielded 10 patients who underwent ESI for spinal malignancy‐related pain. Three patients had “excellent” relief (≥ 50% relief), who all received thoracic injections. This amounted to level IV evidence and an inconclusive recommendation (Grade C) as per Wright’s criteria. In our retrospective review, all thoracic cases achieved at least “moderate” pain improvement (30% to 49% relief). 55.6% had “excellent” relief. Lumbosacral injections resulted in 86.0% with at least “moderate” relief and 69.8% with “excellent” relief. Caudal injections were less likely to benefit than lumbosacral injections (P = 0.02). The transforaminal approach resulted in the best relief. There were no adverse events.Conclusions: There is inconclusive evidence to use ESIs to treat spinal malignancy‐related pain in the current literature. Our retrospective review provides level III evidence for our conclusion that ESIs are safe and efficacious to treat spinal malignancy‐related pain. Thoracic/lumbosacral injections led to significantly better pain relief compared with caudal injections.
- 6 October 2020
- Published by Wiley in Pain Practice
- Vol. 21 (3) , 285-298
Epidural Steroid Injections for the Management of Spinal Malignancy‐Related Pain: A Pragmatic Review and Retrospective Study
Background: Spinal malignancy‐related pain results from tumor, fracture, instability, inflammation, and/or nerve root/spinal cord compression. Systemic corticosteroids are commonly used but have many undesirable adverse effects that impact quality of life and continuation of cancer treatments. Epidural steroid injections (ESIs) may be a viable alternative pain treatment.Objectives: This study starts with a pragmatic review on the efficacy of ESIs to treat spinal malignancy‐related pain. Given the limited evidence, we supplement the study with a single‐center, retrospective review.Methods: A pragmatic review using PRISMA guidelines was conducted in MEDLINE, EMBASE, SCOPUS, and Cochrane Review. Then, a retrospective chart review was performed.Results: A pragmatic review yielded 10 patients who underwent ESI for spinal malignancy‐related pain. Three patients had “excellent” relief (≥ 50% relief), who all received thoracic injections. This amounted to level IV evidence and an inconclusive recommendation (Grade C) as per Wright’s criteria. In our retrospective review, all thoracic cases achieved at least “moderate” pain improvement (30% to 49% relief). 55.6% had “excellent” relief. Lumbosacral injections resulted in 86.0% with at least “moderate” relief and 69.8% with “excellent” relief. Caudal injections were less likely to benefit than lumbosacral injections (P = 0.02). The transforaminal approach resulted in the best relief. There were no adverse events.Conclusions: There is inconclusive evidence to use ESIs to treat spinal malignancy‐related pain in the current literature. Our retrospective review provides level III evidence for our conclusion that ESIs are safe and efficacious to treat spinal malignancy‐related pain. Thoracic/lumbosacral injections led to significantly better pain relief compared with caudal injections.
- 11 April 2020
- Published by Wiley in Pain Practice
- Vol. 20 (7) , 706-713
The Evolving Role of High‐Frequency Spinal Cord Stimulation as Salvage Therapy in Neurostimulation
Background: High‐frequency 10‐kHz spinal cord stimulation (10‐kHz SCS) has shown promise in multicenter prospective trials for the management of chronic back and leg pain. Traditional spinal cord stimulation (t‐SCS) has a long history of effectiveness in chronic neuropathic syndromes but not uncommonly can fail to provide long‐term relief, leaving a significant group of patients with unsatisfactory outcomes. There is mounting evidence that 10‐kHz SCS may offer relief in this subset of patients.Methods: The purpose of this retrospective analysis was to report a single‐institution long‐term experience of 10‐kHz SCS in patients who did not get adequate pain relief with prior t‐SCS devices. A temporary trial of 10‐kHz SCS was carried out for 7 days, and those experiencing an average of 50% reduction in pain intensity underwent implantation. Patients were classified as moderate responders if relief was 31% to 50% and excellent responders if pain relief exceeded 50%.Results: Thirty‐one patients who had experienced failed t‐SCS primarily from poor paresthesia coverage underwent a trial of 10‐kHz SCS and 29 underwent implantation. Twenty‐eight patients were available for analysis, with 57.1% experiencing 30% response and 46.4% experiencing excellent response at a median follow‐up of 21.2 (±8.4) months.Conclusions: This small single‐institution study suggests that a significant proportion of patients with previously failed t‐SCS may achieve clinically meaningful and durable pain relief with 10‐kHz SCS.
- 11 April 2020
- Published by Wiley in Pain Practice
- Vol. 20 (7) , 706-713
The Evolving Role of High‐Frequency Spinal Cord Stimulation as Salvage Therapy in Neurostimulation
Background: High‐frequency 10‐kHz spinal cord stimulation (10‐kHz SCS) has shown promise in multicenter prospective trials for the management of chronic back and leg pain. Traditional spinal cord stimulation (t‐SCS) has a long history of effectiveness in chronic neuropathic syndromes but not uncommonly can fail to provide long‐term relief, leaving a significant group of patients with unsatisfactory outcomes. There is mounting evidence that 10‐kHz SCS may offer relief in this subset of patients.Methods: The purpose of this retrospective analysis was to report a single‐institution long‐term experience of 10‐kHz SCS in patients who did not get adequate pain relief with prior t‐SCS devices. A temporary trial of 10‐kHz SCS was carried out for 7 days, and those experiencing an average of 50% reduction in pain intensity underwent implantation. Patients were classified as moderate responders if relief was 31% to 50% and excellent responders if pain relief exceeded 50%.Results: Thirty‐one patients who had experienced failed t‐SCS primarily from poor paresthesia coverage underwent a trial of 10‐kHz SCS and 29 underwent implantation. Twenty‐eight patients were available for analysis, with 57.1% experiencing 30% response and 46.4% experiencing excellent response at a median follow‐up of 21.2 (±8.4) months.Conclusions: This small single‐institution study suggests that a significant proportion of patients with previously failed t‐SCS may achieve clinically meaningful and durable pain relief with 10‐kHz SCS.
- 30 January 2019
- Published by Taylor & Francis in Pain Management
- Vol. 9 (3) , 225-231
A Review of the Senza System: A Novel, High Frequency 10 kHz (HF10), Paresthesia Free Spinal Cord Stimulator
This article reviews Nevro Corporation's (CA, USA) Senza System high-frequency spinal cord stimulator (HF10 SCS). HF10 therapy has been shown to be noninferior to traditional low-frequency spinal cord stimulation (SCS), and in some studies, has been shown to have long-term effects that are superior compared with traditional low-frequency SCS in treating both back and leg pain. In addition, safety profiles for the HF10 SCS system were equivalent to traditional SCS. HF10 SCS is based on spinal anatomic mapping and does not require intraoperative paresthesia mapping for placement, thereby improving procedural experience for patients and reducing operating room time. HF10 SCS has altered the nature of SCS therapy in a manner that treats more individuals with chronic, refractory leg and back pain than in the past, and is widely used in the USA, Europe and Australia.
- 30 January 2019
- Published by Taylor & Francis in Pain Management
- Vol. 9 (3) , 225-231
A Review of the Senza System: A Novel, High Frequency 10 kHz (HF10), Paresthesia Free Spinal Cord Stimulator
This article reviews Nevro Corporation's (CA, USA) Senza System high-frequency spinal cord stimulator (HF10 SCS). HF10 therapy has been shown to be noninferior to traditional low-frequency spinal cord stimulation (SCS), and in some studies, has been shown to have long-term effects that are superior compared with traditional low-frequency SCS in treating both back and leg pain. In addition, safety profiles for the HF10 SCS system were equivalent to traditional SCS. HF10 SCS is based on spinal anatomic mapping and does not require intraoperative paresthesia mapping for placement, thereby improving procedural experience for patients and reducing operating room time. HF10 SCS has altered the nature of SCS therapy in a manner that treats more individuals with chronic, refractory leg and back pain than in the past, and is widely used in the USA, Europe and Australia.